Polivy and Polyneuropathy - a phase IV clinical study of FDA data

Summary:

Polyneuropathy is reported as a side effect among people who take Polivy (polatuzumab vedotin-piiq), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Bendamustine, and have Non-hodgkin's lymphoma.

The phase IV clinical study analyzes which people have Polyneuropathy when taking Polivy. It is created by eHealthMe based on reports of 2,455 people who have side effects when taking Polivy from the FDA, and is updated regularly.

What is Polivy?

Polivy has active ingredients of polatuzumab vedotin-piiq. eHealthMe is studying from 2,455 Polivy users. Check the latest studies of Polivy.

What is Polyneuropathy?

Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously) is found to be associated with 903 drugs and 944 conditions by eHealthMe. Check the latest studies of Polyneuropathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

2,455 people reported to have side effects when taking Polivy.
Among them, 22 people (0.9%) have Polyneuropathy.

Among these 22 people:

How long have people been on Polivy when they have Polyneuropathy? *

What is the gender of people who have Polyneuropathy when taking Polivy? *

female: 58.82 %
male: 41.18 %

What is the age of people who have Polyneuropathy when taking Polivy? *

What are other drugs people take besides Polivy? *

What are other side effects people have besides Polyneuropathy? *

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 8 people, 36.36%
Lymphoma (cancer that begins in immune system cells): 6 people, 27.27%
Disease Progression: 4 people, 18.18%
Weight Decreased: 3 people, 13.64%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 13.64%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 9.09%
Helicobacter Infection (helicobacter pylori (h. pylori) infects stomach): 2 people, 9.09%
Campylobacter Infection (infection by the campylobacter bacterium): 2 people, 9.09%
Autonomic Neuropathy (malfunction of the autonomic nervous system (ans)): 2 people, 9.09%
Weakness: 1 person, 4.55%

What are the existing conditions these people have? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 18 people, 81.82%

* Approximation only. Some reports may have incomplete information.

Do you take Polivy and have Polyneuropathy?

- Check whether Polyneuropathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Polivy:

Polivy (2,455 reports)

Polyneuropathy treatments and more:

Polyneuropathy (17,901 reports)

Browse all side effects of Polivy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Polyneuropathy:

Polyneuropathy (904 drugs)

Browse all the conditions that are associated with Polyneuropathy:

Polyneuropathy (944 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on polatuzumab vedotin-piiq (the active ingredients of Polivy) and Polivy (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.